(Q36761854)

16 August 2017

1 reference

title

Recent advances in delivery systems for anti-HIV1 therapy (English)

1 reference

16 August 2017

José M Lanao

1

1 reference

16 August 2017

Elsa Briones

series ordinal

2

1 reference

16 August 2017

Clara I Colino

series ordinal

3

1 reference

16 August 2017

publication date

1 January 2007

1 reference

Journal of Drug Targeting

16 August 2017

published in

1 reference

16 August 2017

volume

15

1 reference

16 August 2017

issue

1

1 reference

16 August 2017

page(s)

21-36

1 reference

Tuftsin-bearing liposomes in treatment of macrophage-based infections.

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Targeting to macrophages: role of physicochemical properties of particulate carriers--liposomes and microspheres--on the phagocytosis by macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Virus attachment and entry offer numerous targets for antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Effective transduction and stable transgene expression in human blood cells by a third-generation lentiviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

The current status of gene therapy in autologous transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Sterically stabilized liposomes bearing anti-HLA-DR antibodies for targeting the primary cellular reservoirs of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Human immunodeficiency virus type I as a target for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Current developments in the design of onco-retrovirus and lentivirus vector systems for hematopoietic cell gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Glycosylated macromolecular conjugates of antiviral drugs with a polyaspartamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Human fetal mesenchymal stem cells as vehicles for gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

HIV-1 vectors: fulfillment of expectations, further advancements, and still a way to go.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Microparticles and Nanoparticles as Delivery Systems for DNA Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Lymphoid tissue targeting of anti-HIV drugs using liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Intracellular tracking of protamine/antisense oligonucleotide nanoparticles and their inhibitory effect on HIV-1 transactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Therapeutic immunization strategies for the control of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Gene-based immunotherapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

HIV vaccines: new frontiers in vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Delivery of novel macromolecular drugs against HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Bacterial ghosts are an efficient delivery system for DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

An overview of current delivery systems in cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Vaccinia viral/retroviral chimeric vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Gene therapy for HIV/AIDS: the potential for a new therapeutic regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

A new acyclic heterodinucleotide active against human immunodeficiency virus and herpes simplex virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

New drug combinations for the treatment of murine AIDS and macrophage protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Macrophage protection by addition of glutathione (GSH)-loaded erythrocytes to AZT and DDI in a murine AIDS model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Erythrocytes as carriers of reduced glutathione (GSH) in the treatment of retroviral infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Tuftsin-AZT conjugate: potential macrophage targeting for AIDS therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Virogenomics: a novel approach to antiviral drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Membrane-permeable arginine-rich peptides and the translocation mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Inhibition of HIV-1 envelope glycoprotein-mediated cell fusion by a DL-amino acid-containing fusion peptide: possible recognition of the fusion complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Recombinant poxviruses as mucosal vaccine vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Studies of macromolecular prodrugs of zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Hydroxyurea in the treatment of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Attempts to use liposomes and RBC ghosts as vectors in drug and antisense therapy of virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Carrier erythrocytes: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Enhanced delivery of AZT to macrophages via acetylated LDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

The role of a mutant CCR5 allele in HIV-1 transmission and disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

HIV-1 Tat protein transduction domain peptide facilitates gene transfer in combination with cationic liposomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Suppression of HIV-1 replication by a combination of endonucleolytic ribozymes (RNase P and tRNnase ZL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Toxicology of antisense therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Drug targeting using low density lipoprotein (LDL): physicochemical factors affecting drug loading into LDL particles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Antiretroviral therapy: an update for the non-AIDS specialist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Concepts on the use of liposomal antimicrobial agents: applications for aminoglycosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Efficient transfer of synthetic ribozymes into cells using hemagglutinating virus of Japan (HVJ)-cationic liposomes. Application for ribozymes that target human t-cell leukemia virus type I tax/rex mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Gene delivery systems--gene therapy vectors for cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Receptor ligand-facilitated cationic liposome delivery of anti-HIV-1 Rev-binding aptamer and ribozyme DNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Delivery of an anti-HIV-1 ribozyme into HIV-infected cells via cationic liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

HIV vaccines in infants and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Current developments and future prospects for HIV gene therapy using interfering RNA-based strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Enhanced retroviral gene delivery in ultrasonic standing wave fields

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

HIV-1: hitching a ride on erythrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Therapeutic targets for HIV-1 infection in the host proteome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Drug delivery of oligonucleotides by peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: in vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

FIV infection of macrophages: in vitro and in vivo inhibition by dideoxycytidine 5'-triphosphate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Erythrocyte-mediated delivery of drugs, peptides and modified oligonucleotides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Selective endocytosis of fluorothymidine and azidothymidine coupled to LDL into HIV infected mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Low density lipoproteins as drug carriers in the therapy of macrophage-associated diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Spleen necrosis virus-based vector delivery of anti-HIV-1 genes potently protects human hematopoietic cells from HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Bacterial ghosts as antigen delivery vehicles

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Drug, enzyme and peptide delivery using erythrocytes as carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

In vitro and in vivo transport and delivery of phosphorothioate oligonucleotides with cationic liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Hematologic recovery in mice transplanted with bone marrow stem cells expressing anti-human immunodeficiency virus genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Molecular strategies to inhibit HIV-1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Protein transduction technology offers a novel therapeutic approach for diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Cellular uptake of antisense oligonucleotides after complexing or conjugation with cell-penetrating model peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Red blood cells mediated delivery of 9-(2-phosphonylmethoxyethyl)adenine to primary macrophages: efficiency metabolism and activity against human immunodeficiency virus or herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34(+) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Development of HIV vectors for anti-HIV gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

21 January 2018

THE HIV-1 REV PROTEIN

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Assessment of an anti-HIV-1 combination gene therapy strategy using the antisense RNA and multimeric hammerhead ribozymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Human immunodeficiency virus and host cell lipids. Interesting pathways in research for a new HIV therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Emerging drug targets for antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Acid-induced changes in thermal stability and fusion activity of influenza hemagglutinin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Erythrocyte-mediated delivery of a new homodinucleotide active against human immunodeficiency virus and herpes simplex virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Erythrocyte-based drug delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Inhibition of HIV replication by immunoliposomal antisense oligonucleotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Cyclin-dependent kinases as cellular targets for antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Comparison of HIV- and EIAV-based vectors on their efficiency in transducing murine and human hematopoietic repopulating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Cyclophilin, TRIM5, and innate immunity to HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Current status of bacterial contamination of autologous blood for transfusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Bacterial ghosts--biological particles as delivery systems for antigens, nucleic acids and drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Mechanisms of action of ribavirin in antiviral therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Why do we need new gene therapy viral vectors? Characteristics, limitations and future perspectives of viral vector transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Improved transfection using epithelial cell line-selected ligands and fusogenic peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Gene therapy for HIV infection: what does it need to make it work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Antigen discovery and delivery of subunit vaccines by nonliving bacterial ghost vectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Trim5alpha protein restricts both HIV-1 and murine leukemia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Role of hydroxyurea in treatment of disease due to human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

Involvement of claudin-7 in HIV infection of CD4(-) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860600942178

10.1080/10611860600942178

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference